<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002517</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000078212</org_study_id>
    <secondary_id>EORTC-58921</secondary_id>
    <nct_id>NCT00002517</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells. It is
      not yet known which regimen of combination chemotherapy is more effective for acute myeloid
      leukemia or myelodysplastic syndrome.

      PURPOSE: Randomized phase III trial to compare the effectiveness of different combination
      chemotherapy regimens in treating children who have newly diagnosed acute myeloid leukemia or
      myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of idarubicin vs mitoxantrone in induction and first
           intensification in terms of achieving and maintaining complete remissions in children
           with acute myeloid leukemia or myelodysplastic syndrome.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center
      and disease type (de novo acute myeloid leukemia (AML) vs AML secondary to myelodysplastic
      syndrome (MDS) vs MDS).

        -  Induction: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive cytarabine (ARA-C) IV continuously on days 1 and 2 and then
                IV over 30 minutes every 12 hours on days 3-8, mitoxantrone IV on days 3-5,
                etoposide (VP-16) IV over 1 hour on days 6-8, and ARA-C intrathecally (IT) on days
                1 and 8.

             -  Arm II: Patients receive ARA-C and VP-16 as in arm I and idarubicin IV on days 3-5.

      Patients on both arms with CNS disease at presentation receive ARA-C IT every 3 days until
      the CSF clears and then weekly until the first intensification. After induction, patients on
      both arms proceed to first intensification, regardless of response.

        -  First intensification: When blood counts recover and within 40 days after initiating
           induction, patients are randomized to 1 of 2 treatment arms.

             -  Arm III: Patients receive high-dose ARA-C IV over 3 hours every 12 hours on days
                1-3 (if allogeneic bone marrow transplantation (BMT) is planned) or days 1-4 (if
                allogeneic BMT is not planned) and mitoxantrone IV on days 7-9.

             -  Arm IV: Patients receive high-dose ARA-C as in arm III and idarubicin IV on days
                7-9.

        -  Patients who achieve complete remission (CR) after first intensification and have an
           HLA-identical, chronic myelomonocytic leukemia-nonreactive, sibling donor undergo
           allogeneic BMT. Patients who achieve CR after intensification and have no suitable donor
           receive intensive chemotherapy as defined below. All patients with chloroma at
           presentation undergo local radiotherapy beginning after final intensification.

        -  Second intensification: When blood counts recover, patients receive daunorubicin IV
           continuously, ARA-C IV continuously, VP-16 IV continuously, oral thioguanine, and oral
           dexamethasone on days 1-4 and 11-14 and ARA-C IT on days 1, 4, 11, and 14.

        -  Third intensification: When blood counts recover, patients receive high-dose ARA-C IV
           over 3 hours every 12 hours on days 1-3 and VP-16 IV over 1 hour on days 2-5. When blood
           counts recover, autologous bone marrow is harvested in the event of subsequent relapse.

        -  Maintenance: When blood counts recover, patients receive oral thioguanine daily and
           ARA-C subcutaneously 4 days a month for 1 year.

      PROJECTED ACCRUAL: A total of 310 patients will be accrued for this study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1993</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed acute myeloid leukemia (AML) based on the cytological, cytochemical,
             and immunological criteria of the FAB classification

               -  Must meet 1 of the following criteria:

                    -  More than 30% blasts in marrow (calculation based on the total number of
                       nucleated cells except lymphocytes and plasmocytes)

                    -  Presence of granulocytic sarcoma (chloroma)

               -  Disease must be associated with at least 1 of the following:

                    -  More than 3% myeloperoxidase- or Sudan black-positive blasts

                    -  More than 3% platelet peroxidase-positive blasts

                    -  More than 20% esterase-positive blasts

                    -  Immunological markers compatible with a myeloid differentiation, including 1
                       of the following criteria:

                         -  Blasts positive for myeloid-associated antigen and negative for B- or
                            T-lymphocyte antigens

                         -  Blasts positive for at least 2 myeloid antigens (except CD3 and CD8)

                    -  A cytogenetic abnormality associated with AML OR

          -  Newly diagnosed myelodysplastic syndrome (MDS) based on the cytological and
             cytochemical criteria of the FAB classification

               -  Eligible subtypes:

                    -  Refractory anemia with excess blasts (RAEB)

                    -  RAEB in transformation

                    -  Chronic myelomonocytic leukemia

          -  No promyelocytic leukemia (M3 or M3v) treated with tretinoin (protocol EORTC-06915)

          -  No AML secondary to hematologic or malignant disease other than MDS

          -  Registration must occur within 48 hours of diagnosis

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 15

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

          -  No uncontrolled bleeding disorder

        Hepatic:

          -  Not specified

        Renal:

          -  No renal failure

        Cardiovascular:

          -  No congenital heart disease

        Other:

          -  No encephalopathy

          -  No genetic disorders

          -  No uncontrolled infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No prior antileukemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Behar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Americain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de la Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Esperance</name>
      <address>
        <city>Montegnee</city>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Saint-Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Grenoble - La Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Debrousse</name>
      <address>
        <city>Lyon</city>
        <zip>69322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Section Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Americain</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants (Purpan Enfants)</name>
      <address>
        <city>Toulouse</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Escolar San Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Portugal</country>
  </location_countries>
  <results_reference>
    <citation>Brunet AS, Ploton C, Galambrun C, Pondarré C, Pages MP, Bleyzac N, Freydière AM, Barbé G, Bertrand Y. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2006 Nov;47(6):765-72.</citation>
    <PMID>16333838</PMID>
  </results_reference>
  <results_reference>
    <citation>Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y, Margueritte G, Plouvier E, Boutard P, Vandecruys E, Ferster A, Lutz P, Uyttebroeck A, Hoyoux C, Thyss A, Rialland X, Norton L, Pages MP, Philippe N, Otten J, Behar C; EORTC Children Leukemia Group. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia. 2005 Dec;19(12):2072-81.</citation>
    <PMID>16136166</PMID>
  </results_reference>
  <verification_date>December 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2010</last_update_submitted>
  <last_update_submitted_qc>June 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

